Methotrexate in psoriasis: Revised guidelines

Journal of the American Academy of Dermatology

Volumn 19, Issue 1, 1988, Pages 145-156

  Auerbach, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

DRUG CONTRAINDICATION; HUMAN; LIVER BIOPSY; LIVER DISEASE; ORAL DRUG ADMINISTRATION; PATIENT INFORMATION; PRIORITY JOURNAL; PSORIASIS; REVIEW;

BIOPSY; DRUG ADMINISTRATION SCHEDULE; HUMAN; LIVER; LIVER DISEASES; METHOTREXATE; PATIENT EDUCATION; PSORIASIS;

EID: 0023753821     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(88)80237-8     Document Type: Article

References (99)

1. Methotrexate in psoriasis: a brief review of indications, usage, and complications of methotrexate therapy
2. Position Paper. Methotrexate in rheumatoid arthritis
3. Methotrexate in rheumatoid arthritis
4. The use of methotrexate in rheumatoid arthritis
5. The treatment of severe psoriasis: a national survey
6. Methotrexate guidelines—revised
7. Methotrexate for psoriasis
8. Methotrexate
9. Three decades of folic acid antagonists in dermatology [Commentary]
10. Reappraisal of the use of methotrexate in rheumatic disease
11. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis
12. Cirrhosis associated with methotrexate treatment of psoriasis
13. A comparison of liver ultrasound with liver biopsy histology in patients receiving long-term methotrexate therapy
14. Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes
15. Methotrexate therapy in rheumatoid arthritis: 15 years experience
16. Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis
17. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
18. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in the treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio
19. Hepatotoxicity of prolonged methotrexate therapy for rheumatoid arthritis
20. Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis
21. Ultrasound and radionuclide scans—poor indicators of liver damage in patients treated with methotrexate
22. Liver biopsies from psoriatics related to methotrexate therapy
23. Liver biopsies from psoriatics related to methotrexate therapy
24. Severe liver damage caused by treatment of psoriasis with methotrexate
25. Effects of methotrexate on the liver in psoriasis
26. Hepatotoxicity after long-term methotrexate therapy
27. Methotrexate hepatotoxicity in psoriasis: consideration of liver biopsies at regular intervals
28. A cooperative prospective study of the effects of chemotherapy of psoriasis on liver biopsies
29. Hepatotoxicity of long-term methotrexate therapy for psoriasis
30. Methotrexate and the liver
31. Methotrexate maintenance therapy and liver damage in psoriasis
32. Low-dose methotrexate treatment of rheumatoid arthritis. Long-term observations
33. Psoriasis-liver-methotrexate interactions
34. Cytostatic treatment of psoriasis: Present status
35. Liver biopsy in metho-trexate-treated psoriatics: a reevaluation
36. Methotrexate-induced liver cirrhosis: studies including serial liver biopsies during continued treatment
37. HLA antigens in methotrexate-induced liver cirrhosis
38. Methotrexate-induced liver cirrhosis: a follow-up
39. Renal function in methotrexate-treated psoriatics
40. Renal function and the rate of disappearance of methotrexate from serum
41. Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhea
42. Methotrexate therapy for psoriasis in elderly patients with imparled renal function [letter]
43. Techniques for the measurement of methotrexate in biological samples
44. Clinical pharmacology of methotrexate
45. Methotrexate: bioavailability and pharmacokinetics
46. Low-dose methotrexate kinetics in arthritis
47. Drug interactions with methotrexate
48. Megaloblastic anemia and methotrexate treatment [letter]
49. Clinical pharmacokinetics of methotrexate in psoriasis therapy
50. Intestinal function and methotrexate absorption in psoriatic patients
51. Impact of methotrexate therapy on the folate status of psoriatic patients
52. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption
53. The pharmacology and clinical use of methotrexate
54. Case report: management of methotrexate toxicity in an anephric patient
55. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment
56. Prolongation and enhancement of serum methotrexate concentrations by probenecid
57. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis
58. Inhibition of renal tubular transport of methotrexate by probenecid
59. Drug interactions with methotrexate
60. Methotrexate and nonsteroidal antiinflammatory drugs
61. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole
62. Methotrexate and etretinate as concurrent therapies in severe psoriasis
63. Methotrexate and etretinate as concurrent therapies in the treatment of psoriasis [letter]
64. Risk and prognostic factors in trophoblastic neoplasia
65. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis
66. Methotrexate
67. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study
68. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors
69. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy
70. Studies on human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics
71. Chromosome studies in patients treated with azathioprine and amethopterin
72. Cytogenetic effect of methotrexate on humans cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test
73. Human mitotic and meiotic chromosome damage following in vivo exposure to methotrexate
74. Methotrexate-induced congenital malformation
75. Methotrexate and teratogenesis [letter]
76. Methotrexate-induced congenital malformations
77. Congenital anomalies among children born to mothers receiving chemotherapy for gestational trophoblastic neoplasm
78. Pregnancies after chemotherapy of trophoblastic neoplasms
79. Cytogenetic evaluation of methotrexate-treated psoriatic patients
80. Reproductive performance of women successfully treated for gestational trophoblastic tumors
81. Methotrexate
82. Leukocyte migration inhibition in methotrexate-induced pneumonitis: evidence for an immunologic cell-mediated mechanism
83. Pulmonary disease during the treatment of rheumatoid arthritis with low-dose pulse methotrexate
84. Pulmonary complications following methotrexate therapy
85. Pulmonary function in patients on long-term, low-dose methotrexate
86. Methotrexate-induced pneumonitis
87. Cryptococcosis associated with low-dose methotrexate for arthritis
88. Methotrexate levels, a guide to therapy?
89. Methotrexate and the acquired immunodeficiency syndrome [letter]
90. Pancytopenia associated with low-dose pulse methotrexate in the treatment of rheumatoid arthritis
91. Severe reactivation of sunburn following methotrexate use
92. Small-vessel vasculitis and methotrexate [letter]
93. Delayed reactivation of sunburn by methotrexate: sparing of chronically sun-exposed skin
94. The co-occurrence of Reiter's syndrome and acquired immunodeficiency
95. Methotrexate toxicity in the treatment of generalized pustular psoriasis
96. Treatment of generalized pustular psoriasis with methotrexate and colchicine [letter]
97. Familial juvenile generalized pustular psoriasis
98. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate
99. Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis: evaluation and prognosis based on the study of 104 cases